Conbercept Ophthalmic not checked

Chengdu Kanghong Biotech Co., Ltd. · KH902

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
3 in total
Targets
—
None known yet

What this is

How it works
A decoy protein that soaks up a signal molecule before it can reach the body's cells.-cept: receptor molecules, native or modified WHO name stem
How it’s given
“Subject receive 0.5 mg Conbercept injection into their study eyes every month (Day 0 - Month 5). If subjects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11).”In the company’s words, NCT03223714 on ClinicalTrials.gov
Tested for
Macular Edema (2 trials), Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Retinoblastoma
Main trialPhase 3
“This study evaluates the efficacy and safety of Conbercept ophthalmic injection. This is a multi-center, randomized, double-masked, placebo-controlled phase III clinical study. 237 patients with central retinal vein occlusion(CRVO) are expected to be enrolled in the study and randomly assigned into the Conbercept ophthalmic injection treatment group or the control group at a ratio of 2:1.”In the company’s words, NCT03223714 on ClinicalTrials.gov
Other names
KH902

Other drugs for Macular Edema

All 6 drugs for Macular Edema

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Completed 13 Apr 2020 Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion
Phase 3Completed 13 Apr 2020 Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion
Phase 2Unknown 15 Apr 2023 A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Conbercept Ophthalmic

Following is part of Solo: you see every change to Conbercept Ophthalmic the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in